Novo Nordisk: adjusted GLP-1 sales growth
Novo’s August outlook gives adjusted 2026 sales growth of −6% to 0% at CER. Its adjustments remove specified US 340B provision reversals; reported growth differs.
Novo Nordisk / NVOPublic biotechEarningsDate to watch
What matters
Watch product sales, guidance and cash needs alongside the headline result. Company filings and the earnings release provide the primary evidence.
Primary evidence
Reporting date unconfirmed — research candidate
Novo Nordisk adjusted outlook announcementPublished 2026-08-04
Potential outcome market
Will Novo Nordisk 2026 adjusted sales growth at CER exceed −3%?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.